Entries by Hans Dreijklufft

Impulse for the development of therapy against Katwijkse Ziekte by Amylon Therapeutics

Amylon Therapeutics, a spin-off of Leiden based and NASDAQ-listed ProQR Therapeutics, receives € 300.000 from investment fund UNIIQ to develop a therapy against Katwijkse Ziekte, a disease which is characterized by brain bleedings. The investment was announced by Robert Strijk, City Council Member of Leiden, at the Leidse Schouwburg preceding the startup event HEB LEF 2017 in Leiden.